Immunology: Natural Born Killers: NK Cells and CD8+ T Lymphocytes Flashcards
What are the two types of immunity?
- Innate: non-specific (or broadly specific), immediate response
- Adaptive: highly-specific, delayed response
What cell type do both NK cells and T cells origibate from?
- Both arise from common lymphoid progenitor cells
- Both part of the lymphocyte lineage
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/424/816/a_image_thumb.png?1589467646)
Why do we need cytotoxic lymphocytes?
- We need cytotoxic cells as a means to destroy:
- Cells infected with bacteria, viruses or parasites
- Tumour cells
- Cytotoxic lymphocytes give immune system a way of knowing what is going on inside a cell just by looking at cell surface
What is MHC class I?
- Major histocompatibility (MHC) class I are proteins that are found at the cell surface and form a structure that holds antigenic peptides for surveillance by T cells
What immune system cell recognises MHC class I?
- Recognised by CD8+ cytotoxic T cells
What types of protein can get expressed by MHC class I?
- Proteins expressed within a cell (whether healthy, mutated or resulting from infection)
- NOT JUST VIRAL PROTEINS
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/426/259/a_image_thumb.png?1589468617)
How does viral infeaction of a cell lead to MHC class I antigen presentation and killing of the virally infected cell?
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/426/662/a_image_thumb.png?1589468961)
Describe the structure of MHC class I
- Two polypeptides, non-covalently bound
- α3 and β2-microglobulin provide support to the peptide binding cleft
- α1 and α2 make up the peptide binding cleft
- In humans there are 3 MHC class I genes: HLA-A, -B, -C
- Tissue distribution: all nucleated cells
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/427/088/a_image_thumb.png?1589469142)
MHC class I proteins are central to anti-viral immune responses, so why don’t we see many pathogens that have mutated to avoid antigen presentation?
- There are multiple MHC class I genes - we also inherit two copies of each of these genes
- High genetic variability within these genes
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/428/081/a_image_thumb.png?1589469860)
What part of MHC class I proteins do the majority of MHC polymorphisms (mutations) affect?
- Polymorphisms affect the upper peptide-binding part of the MHC protein
How does genetic variation in MHC class I affect peptide binding?
- Amino acids in the MHC peptide binding groove create pockets where the bound peptide can “anchor”
- These amnio acids have positive/negative charges so by switching these amino acids you get different positive and neagtive charges on the protein
- This changes the size and shape of the pockets in the peptide binding groove which means different peptides bind to different MHC class I alleles
How does the T-cell receptor (TCR) recognise MHC class I when binding?
- TCR recognise two things:
- MHC protein itself
- Antigenic peptide presented by MHC protein
How does the T-cell receptor orientate itself when binding to MHC class I?
- TCR Binds with a diagonal footprint that cuts across both alpha helices of the peptide binding cleft and the antigenic peptide in between
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/431/430/a_image_thumb.png?1589470752)
What role does CD8 play in TCR binding to MHC class I?
- CD8 acts as a co-receptor for MHC-I, and is required for the T cell to make an effective response - strengthens interaction between TCR and MHC class I
- TCR binds to the α1 and α2 domains
- CD8 binds to the support domains (α3 and β2-microglobulin)
- Similar situation for CD4 and MHC-II
![](https://s3.amazonaws.com/brainscape-prod/system/cm/311/432/285/a_image_thumb.png?1589471107)
How do pathogens subvert MHC class I upregulation?
- Inhibit MHC-I transcription (adenovirus)
- Block TAP (Transporter associatd with antigen processing) activity - TAP brings antigens in cytosol to ER (HSV)
- Retain MHC-I in endoplasmic reticulum (adenovirus, HCMV)
- Target MHC-I for disposal from ER (HCMV)
- Downregulate MHC-I from cell surface (HIV)